Literature DB >> 915023

Pharmacokinetics of erythromycin on repetitive dosing.

W A Colburn, A R Di Santo, M Gibaldi.   

Abstract

Serum erythromycin concentration data from several repetitive dosing studies were analyzed with newly developed computer methods for fitting multiple-dose data and generating nonlinear least-squares estimates of pharmacokinetic parameters. This analysis indicates that the pharmacokinetics of erythromycin can be described by a one-compartment linear model with the following characteristics: (a) a lag time between the time of drug administration and the onset of absorption; (b) apparent zero-order rather than first-order absorption; (c) dose-to-dose variability in the rate and extent of absorption; and (d) day-to-day variability in the kinetics of elimination. The bioavailability of the third dose of erythromycin on a given day is considerably lower than that of the second dose or of the fourth and last dose of the day. The average apparent half-life of erythromycin was 1.8 hour on day 1 and 2.6 hours on day 3 of the repetitive dosing regimen.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 915023     DOI: 10.1177/009127007701701006

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  Effect of age on single- and multiple-dose pharmacokinetics of erythromycin.

Authors:  P A Miglioli; P Pivetta; M Strazzabosco; R Orlando; L Okolicsanyi; P Palatini
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1.

Authors:  Tomoki Maekawa; Hikaru Tamura; Hisanori Domon; Takumi Hiyoshi; Toshihito Isono; Daisuke Yonezawa; Naoki Hayashi; Naoki Takahashi; Koichi Tabeta; Takeyasu Maeda; Masataka Oda; Athanasios Ziogas; Vasileia Ismini Alexaki; Triantafyllos Chavakis; Yutaka Terao; George Hajishengallis
Journal:  JCI Insight       Date:  2020-08-06

Review 3.  Requirements for the documentation of pharmacokinetic properties of antimicrobial agents.

Authors:  T Bergan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

4.  Erythromycin acts through the ghrelin receptor to attenuate inflammatory responses in chondrocytes and maintain joint integrity.

Authors:  Tomoya Uchimura; Daisy S Nakamura; Eric M Link; Yoshihiko Noguchi; Satoshi Ōmura; Toshiaki Sunazuka; David J Greenblatt; Li Zeng
Journal:  Biochem Pharmacol       Date:  2019-03-09       Impact factor: 5.858

5.  Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base.

Authors:  K Josefsson; T Bergan; L Magni
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

6.  Pharmacokinetics of single-dose erythromycin in normal and alcoholic liver disease subjects.

Authors:  P D Kroboth; A Brown; J A Lyon; F J Kroboth; R P Juhl
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

7.  Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man.

Authors:  M Ehrnebo; S O Nilsson; L O Boréus
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

8.  Absorption and bioavailability of oral erythromycin.

Authors:  L E Mather; K L Austin; C R Philpot; P J McDonald
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

9.  Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses.

Authors:  T A Tartaglione; A C Raffalovich; W J Poynor; A Espinel-Ingroff; T M Kerkering
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.